demonstrated a dose-dependent inhibition by quinapril of serum and tissue ACE activities and neointima formation.
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Background Angiotensin II (Ang II) induces vascular smooth muscle cell migration and growth in vitro and induces DNA synthesis in vascular smooth muscle in vivo. Angiotensinconverting enzyme (ACE) inhibitors and angiotensin II receptor antagonists inhibit neointimal hyperplasia in many experimental models of restenosis. However, recent clinical trials (MERCATOR and MARCATOR) reported that treatment with low (antihypertensive) doses of an ACE inhibitor (cilazapril) failed to prevent restenosis. Because ACE activity is induced in the neointima after injury, we hypothesize that the inhibition of neointimal development may be dependent on the suppression of tissue ACE activity, which in turn is dependent on the dose of the ACE inhibitor.
Methods and Results To test this hypothesis, we treated rats with increasing doses of an ACE inhibitor, quinapril, before injury of the carotid artery. Blood pressure, serum and tissue ACE activity, and neointimal area were measured. The results O clusive coronary artery disease due to atherosclerosis is a major cause of morbidity and mortality in the United States.1'2 The success of percutaneous transluminal coronary angioplasty, an important treatment strategy, is limited due to restenosis as a result of neointima formation. This neointimal lesion, consisting of smooth muscle cells, fibroblasts, and macrophages, occurs in 30% to 50% of the patients undergoing angioplasty. Despite extensive investigation into the pathophysiology of lesion development in both animals and humans, no effective clinical treatment has been reported. A potential therapeutic regimen for restenosis has been suggested by the recent reports that angiotensinconverting enzyme (ACE) inhibitors block neointimal formation in the balloon-injured rat carotid artery. 3 This inhibition of neointima formation probably is due in part to a decreased production of angiotensin II (Ang II), because specific Ang II receptor antagonists can partially inhibit neointima formation.4 The increase in local bradykinin accumulation may also be involved because a kinin receptor antagonist can partially block the protective effects of the ACE inhibitor.5 The decrease in neointima formation is not due to the decrease in blood pressure observed with ACE inhibitors because verapamil, which also lowers blood pressure, did not affect neointima formation. In vitro data show that Ang II induces cell growth via an increase in the expression of proto-oncogenes and autocrine growth factors in vascular smooth muscle cells,6-9 providing a potential mechanism for the in vivo observations. The mechanism by which bradykinin inhibits growth is less clear but may involve the induction and/or activation of vascular nitric oxide synthase, which ultimately leads to the generation of cyclic GMP, a potent inhibitor of growth.'0"1'
The site of production of Ang II that participates in neointima formation is of interest. ACE exists as a plasma protein as well as a membrane-bound ectoenzyme. We have shown that the developing neointima expresses high levels of ACE after balloon injury.12 Neointimal ACE appears to be present in the smoothmuscle-like cells because immunohistochemical analysis demonstrated that its distribution was similar to a smooth muscle-specific actin and different from that for ED-1, a monocyte/macrophage-specific marker, or von Willebrand factor, an endothelium-specific marker. 12 The induction of tissue ACE expression may explain certain observations concerning the effects of ACE inhibition on neointima formation. The recent MER-CATOR and MARCATOR trials reported'314 that low (antihypertensive) doses of cilazapril did not prevent restenosis in humans. However, careful animal studies showed that, to affect neointima formation, the inhibitor therapy must be initiated before balloon injury.3 Moreover, our results'2 suggest that the doses required to inhibit neointimal development were higher than those necessary for inhibition of circulating ACE.12,15,16
These observations have led us to hypothesize that the inhibition of tissue ACE might be a key determinant of the effect of the drug on neointima formation. The purpose of the present study was to examine the relation between the dose of an ACE inhibitor (quinapril), the suppression of tissue versus serum ACE activities, and the inhibition of neointima formation in experimental restenosis.
Methods

Preparation of Arterial Injury Model
Male Sprague-Dawley rats weighing 500 to 550 g were used. Endothelial denudation and injury to the vascular wall were performed on carotid arteries. Rats were anesthetized with the administration of ketamine hydrochloride (80 mg/kg, Parke-Davis) and xylazine (12 mg/kg, Lloyd Laboratories). A 2F embolectomy balloon catheter (American Edward Laboratories) was passed into the left common carotid via the left external carotid artery according to the previously described method of Clowes et al. 17 Using Evans blue staining, we documented that this procedure denuded the endothelium effectively. The right uninjured carotid artery served as control. On day 12, a PE-10 catheter was inserted into the femoral artery, externalized, and sealed. Twenty-four hours later, direct blood pressures were measured in conscious unrestrained animals. All animals were killed 14 days after injury.
Drugs Administered
The ACE inhibitor quinapril was freshly dissolved in drinking water containing corn syrup (8% vol/vol) and administered to the four groups of rats at 0.05, 0.5, 5, and 50 mg/kg per day.
The consumption of drinking water was measured to confirm sufficient drug intake. Control animals received corn syrup alone.
Morphometric and Biochemical Analysis
On the day they were killed, rats were first anesthetized, and blood was withdrawn from the ascending aorta via the left ventricle. The rats were then perfused at a pressure of 110 mm Hg through the ascending aorta with 100 mL of phosphate-buffered saline (PBS, pH 7.2). The carotid arteries were removed, small segments were fixed in 10% formaldehyde for morphometry, and the remainder was stripped of adventitia and frozen in liquid nitrogen for ACE determination. To estimate the size of the intimal lesion, multiple 5-gm cross sections of each vessel were stained with hematoxylin and eosin. The lesion and the vessel wall were traced carefully using a digitizing tablet (Southern Micro Systems, Model 2200), and the cross-sectional areas of the neointima and the media were calculated.
Serum and tissue ACE activities were determined using a fluorometric assay modified from that described by Cheung and Cushman.'8 This assay measures the generation of His-Leu from a Hippuryl-His-Leu (Sigma Chemical Co). Serum or homogenized vessels were incubated for 15 minutes at 37°C, pH 7.5, in the presence of Hippuryl-His-Leu. To measure background fluorescence, samples were incubated with no added substrate. The reaction was stopped by the addition of NaOH, pH 8.5; the His-Leu was tagged with 0.1% o-phthaldialdehyde (Sigma Chemical Co) and quantitated fluorometrically at an excitation wavelength of 386 nm and emission wavelength of 436 nm. The sensitivity of this assay is less than or equal to 0.1 nmol per tube, and the generation of His-Leu is linear from 0.1 to 13 nmol per tube. ACE activity in the aorta was calculated as nanomoles of His-Leu generated per minute per milligram of protein. Protein was measured by the Bio-Rad protein assay system (Bio-Rad). ACE activity in the plasma was calculated as nanomoles of His-Leu generated per All ACE inhibitors will dissociate from the enzyme over time. However, as recently shown by Husain and coworkers (Kinoshita et al),'9 quinapril exhibits the least washout and slowest dissociation of the inhibitors tested (enalapril, lisinopril, captopril, and quinapril). Furthermore, we have found that the residual ACE activity in tissues from quinapril-treated animals was not affected by a freeze/thaw cycle (Hirsch and Dzau, unpublished data). Moreover, all of the plasma and tissue samples would suffer equally from dissociation.
In additional experiments, the ability of quinapril to inhibit the tissue ACE activity in the in vivo assay was examined. Quinapril (10 ,umol/L) was added to the reaction and incubated for 10 minutes at 37°C before the addition of substrate. The generation of His-Leu was quantified as above.
Statistical Analysis
All results are expressed as the mean±SEM with n=6 or 7. Statistical analysis of the data was performed using ANOVA; P<.05 was considered significant. Multiple pairwise analysis was performed using the Fisher PLSD test. Linear regression was performed and analyzed using sTATVIEw; probability values were calculated using Student's t test.
Immunohistochemistry A mouse monoclonal antibody (IgM class) in ascites fluid, raised against and shown to be specific for rat ACE,20 was purchased from Affinity Bioreagents. The processing of tissue and the preparation of the sections were the same as described above. Briefly, 5--,um sections were cut on a rotary microtome and placed on glass slides that had been treated for 20 seconds with acetone containing 2% 3-amino-propyltriethoxysilane (Sigma Chemical Co). The sections were digested with 0.1% trypsin (Sigma Chemical Co) in PBS at 37°C for 12 minutes. The sections were then preincubated with normal goat serum before incubation with anti-ACE antibody for 15 hours at 4°C. The slides were washed with PBS and incubated with biotinylated goat anti-mouse antibody. After being washed, the sections were incubated with streptavidin-horseradish peroxidase (Zymed Laboratories Inc) and developed with 0.1% 3-amino-9-ethylcarbazole and 0.02% H202 (Signa Chemical Co). The slides then were counterstained with hematoxylin. Positive ACE staining appeared as red-pink in color. As a negative control, the primary antibody was replaced with a nonimmune IgM in ascites produced by the TEPC 183 tumor cell line (Sigma Chemical Co). No staining of the tissue sections was observed in the negative controls.
Results
We have reported previously that the cells in the neointima that developed in response to balloon injury of the abdominal aorta stain positively with an ACEspecific antibody and contain ACE activity.12 Fig 1A shows that the neointima that forms in the carotid artery after similar injury also contains ACE as evidenced by intense immunohistochemical staining with the anti-ACE antibody. Weak, diffuse staining was also observed in the medial layer. In the uninjured vessel ( Fig 1B) , weak staining was observed in the endothelial layer with weak, diffuse staining observed occasionally in the media. The staining was specific, since the controls were negative (Fig 1C and 1D) . Consistent with our results on the effects of balloon injury on levels of ACE activity in the aorta, the activity in the injured carotid artery was higher than in the contralateral uninjured vessel (3.82±0.23 nmol/min per milligram of protein, injured, versus 2.45+±0.31 nmol/min per milligram of protein, uninjured, n=6). Rats received quinapril (0.05 to 50 mg/kg per day) or vehicle starting 6 days before balloon injury and continuing until 14 days after injury. Twelve days after injury, a PE-10 catheter was placed in the femoral artery, externalized, and sealed. Twenty-four hours later, direct blood pressures were measured in conscious unrestrained animals (A). Fourteen days after injury, the animals were anesthetized, blood was collected via the ascending aorta, and the carotid artery was perfused with phosphate-buffered saline. The residual activity of serum (B) and vascular ACE in the injured (C) and uninjured (D) vessels was measured in each animal. In addition, a small section from each vessel was fixed in 10% formaldehyde and analyzed morphometrically for neointima formation (E). The results are expressed as mean±SEM for n=6 or 8 per group. *P<.05 compared with vehicle-treated animals. Note the differences in dose response between the quinapril dose and blood pressure and serum ACE compared with the response of tissue ACE or neointimal area.
quinapril resulted in significant decreases in blood pressure. Serum ACE activity was also significantly reduced in animals receiving 5 and 50 mg/kg per day, exhibiting an 88.5% inhibition at 50 mg/kg per day ( Fig  2B) . On the other hand, tissue ACE activity was less sensitive to in vivo ACE inhibitor therapy and was only significantly suppressed by the highest dose (50 mg/kg per day, Fig 2C) . The inhibition of ACE activity in the uninjured vessel exhibited a dose response similar to that seen in the injured vessel, with a 57% inhibition noted at 50 mg/kg per day (Fig 2D) . When the neointimal area (expressed as the ratio of neointimal to medial area) was measured, a parallel pattern of inhibition was noted, ie, 53% at 50 mg/kg per day (Fig 2E) . Because neither injury nor ACE inhibitor treatment affected the area of the media,'2 expression of the results as neointimal area did not alter the results (data not shown). We next examined if the inability of the ACE inhibitors to completely inhibit tissue ACE activity was due to the presence of other enzymes that are capable of cleaving the Hippuryl-His-Leu. Quinapril was added to the tissue homogenate before the addition of substrate.
The results indicate that addition of quinapril to the in vitro ACE assay inhibited ACE activity in the plasma and tissue homogenates to similar extents (serum ACE, 99%; vascular ACE from injured vessels, 82.5%; vascular ACE from control vessels, 80.0%; rat lung homoge-nate, 98%; purified human renal ACE, 78%; n=2). Therefore, a majority of the residual "ACE activity" is probably authentic ACE with a smaller contribution of activity that is not quinapril sensitive.
The concordant inhibitions of tissue ACE activity and neointimal area led us to hypothesize that the suppression of tissue ACE activity plays a role in blocking neointima formation. To examine further the contribution of the various factors to neointima inhibition, we examined the correlation between neointima size, blood pressure, and residual tissue and plasma ACE activities in the treated animal (Fig 3) . The blood pressure as a result of treatment did not correlate with the size of the neointima (r=.252, P=.35). Interestingly, a strong correlation was demonstrated between posttreatment neointima size and the residual tissue ACE activity after ACE inhibitor treatment (r=.88, P=.0001). A significant but weaker relation existed between posttreatment neointima size and the residual serum ACE activity (r=.548, P=.01). Discussion
The above data describe a dissociation of the effects of an ACE inhibitor on the plasma ACE activity and blood pressure from its effects on tissue ACE activity. These results suggest that the need for a higher dose of an ACE inhibitor for the inhibition of neointima formation may be due to the relative difficulty in inhibiting tissue ACE activity. Multiple lines of evidence suggest that Ang II plays a role in the regulation of vascular structure. ACE inhibitors inhibit hypertension-induced vascular hypertrophy by a mechanism that is not solely dependent on the decrease in blood pressure, since treatment with hydralazine did not inhibit the hypertrophy to the same extent despite equal lowering of the pressure.21 Infusion of Ang II into rats results in vascular hypertrophy of noninjured vessels and enhances neointima formation in balloon-injured vessels.22 ACE inhibitors have been shown to inhibit neointima formation in response to injury in rats4 and guinea pigs23 and the allograftinduced intima formation in rats. 24 Moreover, recent evidence suggests that ACE inhibitors also inhibit the development of atherosclerosis in Watanabe rabbits25 or cholesterol-fed primates26 and inhibit the migration of monocytes into the vessel wall. 27 We have extended these studies using in vivo gene transfer. In preliminary studies, the expression of a transfected ACE gene in the vessel wall results in an increased rate of DNA synthesis in the vascular smooth muscle cells,28 demonstrating that increases in local ACE activity can directly increase vascular growth.
The mechanism of Ang Il-induced growth has been examined using cultured vascular smooth muscle cells. Ang II induces the expression of the proto-oncogenes c-fos, c-jun, and c-myc and the autocrine growth factors platelet-derived growth factor, fibroblast growth factor, and transforming growth factor-..7-9 The expression of these growth factors within the vessel wall after injury suggests that these factors may contribute to Ang IIinduced neointima formation.
ACE inhibitors are expected to inhibit growth of vascular smooth muscle cells via multiple pathways. As discussed above, Ang II is directly involved in the induction of both hypertrophic and hyperplastic growth of these cells. Less well understood is the action of kinins, which in the intact vessel may act indirectly via the stimulation of endothelial-dependent vasodilators such as endothelium-derived relaxing factor and pros-taglandins29,30 but may also have a direct effect on vascular smooth muscle cells. Because these endogenous vasodilators have also been shown to be capable of inhibiting growth of vascular smooth muscle cells, the inhibition of ACE-mediated kinin degradation may contribute to the growth-inhibitory action of ACE inhibitors. The relative contributions of Ang II decrease and kinin increase to the antigrowth effect of ACE inhibitors are unclear. It has been shown that Hoe 140 (D-Arg, [Hyp3, Thi5, D-Tic7, Oict]-bradykinin), a kininreceptor antagonist, will blunt the inhibitory effect of ACE inhibitors on neointima formation.5,31 Moreover, while the Ang II receptor antagonist DuP 753 can also blunt neointima formation,4'5 the inhibitory effect of the receptor antagonist does not appear to be as complete as that of the ACE inhibitors. On the other hand, Ang II infusions can overcome the blockade of lesion development by ACE inhibitors,4 suggesting that the decrease in Ang II plays a role. Thus, while the exact mechanism by which ACE inhibitors prevent neointima formation is unclear, we believe that both the decrease in Ang II production and the increase in bradykinin are important.
Previously, we have shown that the neointima that forms after balloon injury of the aorta expresses ACE activity and stains intensely with antibodies raised against either rat or human ACE.12 Positive immunostaining was localized to smooth muscle-like cells, since the distribution of staining was distinct from those of markers of endothelial cells (von Willebrand factor) or monocytes/macrophages (ED-1) but was identical to the distribution of staining for a smooth muscle actin. Moreover, in culture, smooth muscle cells from the normal adult media express only low levels of ACE, whereas our preliminary results demonstrate that smooth muscle cells from neonates, which share many properties with neointimal smooth muscle cells,32-34 express high levels of ACE. 35 Taken together, these results are consistent with the hypothesis that the neointima is populated with smooth muscle cells that express a dedifferentiated phenotype.
One explanation of our data is that tissue ACE plays a major role in the development of the neointimal lesion. However, an alternate interpretation is that the ACE activity in the injured vessel is simply a marker for the neointima and that the decrease in tissue ACE is not causally related to the decrease in neointimal area. We favor the former explanation for the following reasons. First, the inhibition of ACE activity in the uninjured vessel exhibited a dose response similar to that noted in the injured vessel. We have previously shown that a large fraction of the vascular ACE found in the uninjured vessel is not associated with the endothelial cells but is found in the medial layer.12 Therefore, the dose response for inhibiting ACE activity in the uninjured vessel wall is indicative of the relative difficulty in inhibiting ACE within the vessel wall. Taken together, this suggests that the level of ACE is not simply a marker for the lesion but may in fact represent the inability of quinapril to completely inhibit vascular "ACE activity." Moreover, the evidence from others that ACE inhibitors exert their action locally15'16 and that local ACE plays a role in local function and regulation36-39 is consistent with this interpretation. Finally, as mentioned above, preliminary results indicate that, in vivo, the over-expression of a transfected ACE gene in the vessel wall results in increased DNA synthesis in smooth muscle cells,28 demonstrating that increases in local ACE activity can increase vascular growth. However, more work is required to prove definitively this hypothesis. The importance of these findings for restenosis in humans remains to be elucidated. Of obvious importance is the design of clinical studies to evaluate the effect of ACE inhibition on restenosis after angioplasty. Our findings suggest that the dose of ACE inhibitors should be sufficiently high to effectively block tissue ACE activity. The recent MERCATOR and MARCA-TOR trials1314 using low (antihypertensive) doses of cilazapril reported that restenosis was not prevented. While this dose may be sufficient to reduce blood pressure, the results presented here suggest that the dose necessary to inhibit neointima formation is clearly higher than the hypotensive dose. Species-specific differences in the action of the ACE inhibitors toward the development of the neointima cannot be ruled out, especially in light of the report that cilazapril does not inhibit neointimal development in the balloon-injured baboon. 40 Further clinical studies using sufficient ACE inhibitor doses are needed to test the angiotensin hypothesis in human restenosis.
